eFFECTOR Therapeutics (EFTR) to Release Quarterly Earnings on Friday

eFFECTOR Therapeutics (NASDAQ:EFTR) will be issuing its quarterly earnings data on Friday, March 8th.

eFFECTOR Therapeutics Trading Down 10.1 %

Shares of eFFECTOR Therapeutics stock traded down $1.69 during trading on Thursday, hitting $14.99. 158,895 shares of the stock were exchanged, compared to its average volume of 135,981. The stock has a market capitalization of $38.67 million, a price-to-earnings ratio of -0.79 and a beta of 0.52. The company has a fifty day moving average price of $11.80 and a 200-day moving average price of $13.37. eFFECTOR Therapeutics has a 1-year low of $8.44 and a 1-year high of $37.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp acquired a new position in shares of eFFECTOR Therapeutics during the 1st quarter worth approximately $68,000. Renaissance Technologies LLC acquired a new position in shares of eFFECTOR Therapeutics during the 2nd quarter worth approximately $42,000. Two Sigma Investments LP acquired a new position in shares of eFFECTOR Therapeutics during the 3rd quarter worth approximately $27,000. Northern Trust Corp grew its position in shares of eFFECTOR Therapeutics by 336.8% during the 4th quarter. Northern Trust Corp now owns 160,812 shares of the company’s stock worth $75,000 after purchasing an additional 123,998 shares in the last quarter. Finally, Sea Otter Advisors LLC acquired a new position in shares of eFFECTOR Therapeutics during the 1st quarter worth approximately $93,000. Institutional investors and hedge funds own 57.67% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price target on shares of eFFECTOR Therapeutics to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 6th.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.